Answers are grounded in this paper and cite their sources.
Novel non-acidic lonazolac analogues with high COX-2 selectivity and good safety profile, having potential anti-inflammatory activity.
No takes yet. Share an insight, caveat, or question.
Harras et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: